GSP藥品管理軟件,推銷一筆1000元(一個連鎖店會有多筆,多勞多得) 注意:本任務終端客戶僅限于西南地區(qū)(四川、重慶、云南、貴洲、西藏),其他地區(qū)的酬勞面談 本軟件 是專門為醫(yī)藥零售、零售連鎖、醫(yī)藥批發(fā)企業(yè)開發(fā)的專用軟件,完全符合GSP規(guī)范。亦適合于大、中、小型商業(yè)百貨零售及批發(fā)、連鎖企業(yè)。本系統(tǒng)達到了標準的現(xiàn)代化物流管理及全面品質(zhì)管理要求。有助醫(yī)藥商業(yè)企業(yè)全面實現(xiàn)電子化、自動化、標準化的現(xiàn)代化先進管理模式。它分工明確,對于各個不同部門實現(xiàn)不同的功能,各行其責,便于管理。 本系統(tǒng)集醫(yī)藥商業(yè)企業(yè)的質(zhì)量管理、批發(fā)、零售、連鎖店配貨以及進、銷、存各項自動化管理功能于一體。系統(tǒng)采用開放式、組件化、平臺化設計,可根據(jù)個別企業(yè)的不同需要增加或修改功能,達到度身定做的目的。信息數(shù)據(jù)資料庫可無限量擴容,完全適合商業(yè)企業(yè)的現(xiàn)在直至未來的快速發(fā)展需求。 產(chǎn)品名稱版 本零售價(元) 藥房管理系統(tǒng) (HIS系統(tǒng))單體店版(單機版)1500 批發(fā)店版(網(wǎng)絡版)1800 連鎖店版(網(wǎng)絡版)2000 醫(yī)院管理系統(tǒng)標準版(網(wǎng)絡版)3000 診所管理系統(tǒng)標準版(網(wǎng)絡版)2500 每兩個點(電腦)為一筆,一個批發(fā)企業(yè)會有多個點, 請在銷售成功(收到首付款)后,在此提交稿件,每一筆提交一份稿件,獲取賞金1000元。
Enriching Low-Abundance Serum & Plasma Proteins AWARD: $30,000 USD | DEADLINE: 10/01/11 | ACTIVE SOLVERS: 254 | POSTED: 8/01/11 Source: InnoCentive Challenge ID: 9932714 Type: Theoretical-licensing Detailed Description & Requirements Concentrations of proteins in serum and plasma span up to 10 orders of magnitude – e.g. from serum albumin (50 mg/ml) to some cytokines and chemokines (<5 pg/ml) Protein molecules most useful to researchers exist at levels that are approximately at or below the 10,000 pg/ml range. Detection and quantification of these low-abundance proteins is obscured by the presence of high abundance proteins. Current methods for reducing the concentration of high-abundance proteins are either inefficient, targeted at certain proteins, or introduce bias and other artifacts. The Seeker is looking to identify novel methods to reliably reduce or eliminate high abundance proteins so that detection of protein analytes present at the 1-10 ng/ml scale or lower may be accurately detected. The Seeker envisages that a sample preparation techniques may be the most likely route to a solution. However, alternative approaches are also welcomed. The Seeker is highly experienced in sample preparation technologies for reduction of high-abundance proteins & is not interested in simple proposals of commercially available, or published, technologies and techniques. The Seeker is aware of the following ‘sample enrichment’ technologies for reducing the concentration of high abundance proteins from serum & plasma. The techniques are listed together with their limitations for the Seeker: Immunoaffinity depletions– depletions are extremely specific to the antigens the antibodies target. Commercially available kits commonly deplete 6-20 high abundance proteins with more than 90% efficiency. Although this enables detection of more low-abundance proteins, the column-based process induces some bias in low-abundance protein populations. Dye affinity depletions- Depletion of albumin using immobilized dyes such as Cibacron Blue. Limitations are that only albumin is depleted and proteins/peptides that interact with albumin are removed. Lectin affinity enrichments– low-abundance glycoproteins can be concentrated from serum/plasma using various lectin-binding procedures. Although efficient and specific, lectin enrichment introduces bias in the processed sample and results vary greatly depending on the techniques used. Peptide/nucleotide affinity reagents–methods based on interactions between abundant proteins and synthetic peptides or nucleotides (i.e. aptamers). Aptamers are fraught with non-specific and low affinity interactions and therefore are not desirable as a method of enrichment. The Seeker is not interested in a literature review and suggestions of possible techniques. Instead, the seeker requires a novel technology or technique that will dramatically (99.9% efficient) reduce, or eliminate, high abundance (>10 ng/ml) proteins from serum & plasma. Although a ‘universal’ solution is preferred, the Seeker is also interested in solutions that reduce or eliminate only certain classes of protein. Sample size and source is important – proposed technologies should be amenable to working with 50-1000 μl. Although human plasma and serum are the priority samples, the Seeker would ideally like to employ the successful technology on other mammalian sera and plasma. A ready-to-use method that offers good ease of use, efficacy and reproducibility is desired. However, the Seeker is willing to develop promising technologies and protocols in partnership with Seekers they judge suitable. Proposed solutions should fulfill the following Technical Requirements: 1. Sample preparation technologies must: a. Be novel (not described in literature or commercially available) b. Be suitable for use with 50-1000 μl volumes c. Deplete high abundance proteins (>10 ng/ml) or large groups of proteins by 99.9% or more d. Not deplete or denature the low-abundance proteins. The Seeker is willing to accept some slight modification of low-abundance proteins or some bias in low-abundance proteins following the procedure. However, any bias or modification must be highly reproducible. 2. Prepare sample that are: a. Depleted of proteins present at concentrations above 10 ng/ml b. Suitable for use in Mass Spectrometry 3. The method should be adaptable for high throughput applications. Cost must not be prohibitive. Project Criteria This is a Theoretical Challenge that requires only a written proposal to be submitted. The submitted proposal should include the following: · A thorough description of the proposed method(s) or technologies & their mechanisms of action. · A listing of any specialized reagents or materials required, including suppliers if known · An extensive protocol for use of the technology or a roadmap for development of a suitable technology. · A list of the technologies limitations for the stated application. · A detailed explanations as to why Solver believes that the proposed solution meets the Requirements listed above. Literature references supporting the approach should be included. · Solvers who propose a solution similar to the methods listed above should include explanations as to how their proposed solution overcomes their limitations. · References to practical experience which a Solver may have in the field and an indication of the Solver’s availability to collaborate with the Seeker in developing a solution. The proposal should not include any personal identifying information (name, username, company, address, phone, email, personal website, resume, etc.) The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, they will grant to the Seeker non-exclusive license to practice their solutions. 應征稿件請直接上傳到:https://www.innocentive.com
Seeking a 6/7/5 Annulated Ring System AWARD: varies | DEADLINE: 10/31/11 | ACTIVE SOLVERS: 30 | POSTED: 8/31/11 Material supply of non-commercial compoundsmatching the shown core structure is desired. The Seeker intends to award multiple Solvers for each of theirqualifying submissions. In order to submit to this Challenge, youmust allow the Seeker to view the structure of your compound in the StructureSelection stage of the Challenge. Intellectual Property: In return for the Initial Transfer Fee of$300 or $500 per compound, you are expected to grant the Seeker only anon-exclusive license to test your compound(s) in their in-house assays and/or usethe compound(s) to prepare other compounds for in-house testing. Source: InnoCentive Challenge ID: 992765 更多要求見附件